Ketabon is working to develop a medication that harnesses ketamine’s antidepressant effects without the safety issues that ...

With three FDA approvals in the past 10 months, there is a lot of momentum in the Duchenne muscular dystrophy space. Here are ...

Jeffrey Chamberlain, president of the American Society of Gene & Cell Therapy, spoke with BioSpace about what we can expect ...

Adeno-associated viruses have long been go-to vectors for gene therapies. How AAVs are improving will be among the cell and ...

FDA Commissioner Robert Califf has said that advisory committee meetings should focus more on discussion and be “less about ...

Despite being hit with a 20% sales decline due to a plunge in demand for its COVID-19 products, Pfizer on Wednesday reported ...

AstraZeneca’s blockbuster BTK inhibitor Calquence significantly improved progression-free survival when used as a frontline ...

In a bid to improve competition in the industry, the U.S. Federal Trade Commission is challenging the patents of 20 different ...

Based on strong overall and progression-free survival data in its Phase III confirmatory study, Pfizer and Genmab’s ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu significantly improved progression-free survival in ...

Boehringer Ingelheim on Wednesday won the FDA’s approval for a high-concentration and citrate-free version of its Humira ...

With GLP-1 agonists slated to become the best-selling drugs in 2024, the biopharma industry is already pivoting to explore ...